MetLife’s latest quarter reflected steady execution across its global insurance and investment businesses, with results generally in line with Wall Street’s expectations and little movement in the share price. Key drivers included broad-based growth across operating segments, favorable variable investment income from private equity and venture capital, and disciplined expense control amid ongoing integration of PineBridge Investments. CEO Michel Khalaf emphasized the contribution of both capital-light and capital-driven earnings engines, noting, “No single business drove results. That breadth is the central strength of MetLife.”

Is now the time to buy MET? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from MetLife’s Q3 earnings call

• Ryan Krueger (KBW): asked about the composition of the non-medical health loss ratio, particularly the impact of disability claims. Head of U.S. Business Ramy Tadros explained that while disability severity increased, recoveries and claim management offset much of the impact, keeping results within target range.
• Suneet Kamath (Jefferies): inquired about the sustainability of favorable working-age mortality trends and their pricing implications. Tadros responded that while some benefit may gradually normalize, the competitive market and renewal cycles mean changes will play out over years, not quarters.
• Tom Gallagher (Evercore ISI): questioned the outlook for disability pricing amid rising industry claims. Tadros indicated that rational industry pricing and MetLife’s bundled product approach should support necessary rate adjustments in response to trends.
• Wes Carmichael (Wells Fargo): asked about the direction of free cash flow conversion and the balance between growth investments and capital returns. CFO John McCallion reaffirmed comfort with the 65%-75% target, noting simultaneous growth and strong cash generation.
• Alex Scott (Barclays): requested insight into expense ratio trends post-PineBridge acquisition and the impact of technology on future expense discipline. CEO Michel Khalaf highlighted that AI-driven productivity and tight cost management are expected to drive the ratio down further over time.

Catalysts in upcoming quarters

In the coming quarters, our analysts will watch (1) signs of sustained expense ratio improvement as AI and digital initiatives scale, (2) ongoing diversification and profitability of MetLife’s global insurance and investment businesses, and (3) continued execution on capital deployment through both organic growth and selective acquisitions. The pace of normalization in underwriting margins and momentum in digital partnerships like Revolut will also be key areas of focus.

MetLife currently trades at $100.82, down from $102.89 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.